Public Company Edition: BioAge will fund a Phase II trial of its muscle atrophy prevention drug in combination with an obesity drug with its initial public offering proceeds. Also, Ascendis and Wave raised $281.3m and $200m, respectively, after positive clinical trial readouts.

The move is positive for manufacturers and follows the agency’s decision to drop another contentious proposal that would have ‘stacked’ drug discounts when calculating Medicaid best prices.

The withdrawal amid concerns about the risk-benefit ratio reduces treatment options for sickle cell disease, but it is not expected to have much effect on the SCD market, including the gene therapies.

The withdrawal amid concerns about the risk-benefit ratio reduces treatment options for sickle cell disease, but it is not expected to have much effect on the SCD market, including the gene therapies.